hiv
envelop
protein
play
critic
role
hiv
entri
thu
extrem
interest
develop
novel
therapeut
studi
divers
method
includ
structur
biolog
mutagenesi
result
detail
model
envelopemedi
entri
consist
multipl
conform
potenti
target
therapeut
intervent
review
discuss
challeng
strategi
progress
date
develop
novel
entri
inhibitor
direct
disrupt
hiv
function
human
immunodefici
viru
hiv
caus
agent
aid
devast
diseas
result
million
death
newli
infect
million
peopl
year
hiv
envelop
protein
play
critic
role
entri
process
thu
focu
intens
studi
review
see
synthes
precursor
undergo
number
matur
step
includ
format
disulfid
bond
extens
glycosyl
cleavag
cellular
furinlik
proteas
transport
cell
surfac
noncoval
membran
complex
final
incorpor
bud
viru
shown
figur
compos
five
conserv
domain
five
variabl
domain
compos
seven
domain
ntermin
fusion
peptid
heptad
repeat
disulfid
loop
heptad
repeat
membran
proxim
ectodomain
region
mper
transmembran
cytoplasm
base
sequenc
homolog
envelop
protein
two
type
hiv
term
well
siv
homolog
found
simian
exhibit
sequenc
ident
preval
compris
subtyp
clade
b
c
e
primari
differ
length
sequenc
variabl
loop
recent
signific
progress
made
understand
hiv
envelop
structur
function
structur
mutagenesi
studi
follow
suggest
envelop
present
abund
target
site
therapeut
intervent
addit
summar
potenti
intervent
strategi
discuss
progress
date
due
critic
role
hiv
entri
envelop
protein
hiv
homolog
found
siv
extens
studi
structur
techniqu
xray
crystallographi
nmr
spectroscopi
hope
structur
knowledg
may
exploit
design
entri
inhibitor
vaccin
howev
due
technic
difficulti
includ
insolubl
membraneassoci
protein
presenc
metast
conform
extens
glycosyl
dynam
region
structur
studi
date
limit
isol
domain
structur
inform
xray
nmr
studi
includ
overal
fold
core
figur
ectodomain
trimer
figur
receptor
bind
site
structur
chang
core
upon
receptor
bind
structur
fusion
peptid
lipid
environ
structur
mper
import
target
neutral
antibodi
togeth
structur
studi
suggest
complex
undergo
seri
conform
chang
entri
process
nonetheless
mani
detail
miss
includ
highresolut
structur
inform
interact
well
structur
inform
numer
domain
absent
avail
structur
figur
inde
complex
list
journal
natur
th
desir
structur
obtain
biolog
mani
challeng
remain
achiev
goal
altern
approach
structur
biolog
mutagenesi
use
great
effect
map
function
specif
region
envelop
give
topolog
inform
complex
exampl
sitespecif
mutagenesi
studi
given
insight
function
role
conserv
domain
fusion
peptid
disulfid
loop
mper
domain
interestingli
mani
mutant
nonfunct
entri
even
rel
conserv
chang
alanin
substitut
threonin
observ
somewhat
surpris
given
envelop
mutat
readili
presum
avoid
immun
system
maintain
function
howev
sensit
envelop
mutat
might
suggest
mani
site
potenti
target
therapeut
intervent
exampl
small
molecul
peptid
protein
bind
rel
high
affin
sensit
region
could
expect
disrupt
envelop
function
ie
hiv
entri
mutagenesi
combin
structur
inform
given
import
insight
interact
structur
inform
absent
summar
figur
mutat
result
dissoci
viral
cellular
membran
ie
suggest
residu
direct
intermolecular
contact
altern
residu
proxim
contact
accordingli
put
contact
ctermin
region
disulfid
loop
observ
support
recent
biochem
studi
addit
inform
associ
come
studi
binley
et
al
shown
interact
disulfid
loop
deduc
presenc
nonn
intermolecular
disulfid
seri
cystein
scan
mutant
interestingli
best
character
mutant
term
so
function
nonn
disulfid
bond
reduc
suggest
conform
chang
associ
perhap
dissoci
critic
function
underscor
import
conform
chang
hiv
entri
final
mutat
envelop
could
also
serv
stabil
construct
particular
conform
make
amen
structur
studi
use
vaccin
candid
base
structur
function
studi
hiv
siv
envelop
construct
well
structur
studi
analog
envelop
protein
ebola
viru
influenza
viru
paramyxoviru
sar
coronaviru
box
evolv
model
hiv
entri
aris
shown
figur
model
depict
three
step
envelopemedi
entri
bind
viru
target
receptor
ii
tether
viru
target
membran
iii
fusion
viral
target
membran
initi
step
associ
receptor
form
state
subsequ
associ
chemokin
receptor
cr
specif
cell
type
form
receptorbound
state
stage
structur
rearrang
occur
complex
possibl
dissoci
allow
exposur
heptad
repeat
term
insert
ntermin
region
hydrophob
region
term
fusion
peptid
target
membran
form
tether
state
extend
metast
form
rel
shortliv
final
step
undergo
conform
chang
bring
togeth
form
fusion
state
therebi
bring
plasma
viral
membran
close
proxim
promot
fusion
recent
evid
fusion
might
actual
occur
endosom
membran
simplic
shown
monom
figur
gener
thought
trimer
three
step
entri
howev
vitro
vivo
evid
exist
monomertrim
equilibrium
thu
infect
process
could
significantli
complex
importantli
electron
tomographi
studi
advantag
studi
envelop
structur
situ
ie
context
viral
membran
confirm
trimer
natur
envelop
addit
give
novel
insight
interact
envelop
receptor
viral
membran
note
evid
extend
conform
ie
tether
state
depict
figur
come
analog
influenza
ha
protein
structur
extend
compact
form
furthermor
peptid
correspond
potent
antivir
presum
act
bind
extend
expos
conform
therebi
block
format
fusion
state
summari
three
step
envelopemedi
entri
requir
complex
exist
least
four
distinct
conform
free
receptorbound
tether
fusion
hiv
envelop
present
number
challeng
develop
entri
inhibitor
well
vaccin
note
structur
detail
prerequisit
structurebas
strategi
miss
mani
part
hiv
entri
model
figur
furthermor
hiv
evolv
rel
intract
human
immun
system
use
number
strategi
also
relev
design
entri
inhibitor
first
hiv
revers
transcriptas
error
prone
thu
mutat
readili
occur
hiv
protein
howev
discount
variabl
domain
envelop
residu
highli
conserv
siv
suggest
region
abl
mutat
without
significantli
affect
envelop
function
notion
clearli
support
mutagenesi
studi
mention
second
mani
conserv
envelop
region
might
access
due
high
level
glycosyl
variabl
loop
rel
high
mobil
sometim
refer
glycan
shield
counterintuit
monoclon
antibodi
neutral
multipl
clade
bind
glycosyl
moieti
nonetheless
sequenc
variabl
glycosyl
mobil
make
envelop
move
target
complic
search
molecul
bind
high
specif
despit
highli
conserv
region
transient
expos
would
expect
attract
site
therapeut
intervent
would
suggest
mediev
armor
knight
analog
battl
knight
hiv
envelop
rel
impervi
attack
eg
bind
entri
inhibitor
sword
thrust
bind
receptor
target
membran
knight
underarm
briefli
expos
context
envelop
could
present
conserv
site
potenti
therapeut
intervent
note
transient
exposur
target
site
could
also
due
breath
envelop
ie
fluctuat
conform
lowest
energi
state
well
transient
state
present
entri
process
eg
tether
state
shown
figur
importantli
strategi
exploit
transient
state
extrem
import
date
discuss
detail
hiv
envelop
attract
target
therapeut
immunolog
intervent
hiv
entri
discuss
intervent
advantag
occur
viru
enter
cell
oppos
tradit
antihiv
therapi
inhibit
downstream
viral
process
revers
transcriptas
integr
proteolyt
process
ie
revers
transcriptas
integras
proteas
inhibitor
abrog
necess
therapeut
cross
cellular
membran
importantli
entri
inhibitor
attract
candid
microbicid
design
prevent
sexual
transmiss
hiv
gener
entri
inhibitor
could
includ
small
druglik
molecul
peptid
protein
antibodi
box
could
direct
viral
target
ie
cellular
target
ie
cr
disadvantag
target
human
protein
normal
cell
function
could
disrupt
result
undesir
side
effect
howev
resist
due
mutat
less
problemat
cellular
target
viral
target
mutat
readili
therapeut
intervent
could
occur
three
step
shown
figur
well
format
free
state
importantli
mutagenesi
studi
suggest
bind
therapeut
antibodi
mani
site
would
sever
disrupt
hiv
entri
perhap
alloster
manner
hiv
entri
inhibitor
discov
date
divid
three
class
target
format
free
state
ie
interfer
envelop
matur
ii
target
format
receptorbound
state
ie
disrupt
bind
andor
cr
iii
target
format
fusion
state
ie
bind
tether
state
follow
section
give
exampl
class
inhibitor
proteolyt
cleavag
furin
furinlik
proteas
shown
critic
hiv
envelop
function
thu
inhibit
cellular
furin
possibl
strategi
therapeut
intervent
aforement
advantag
disadvantag
target
cellular
target
interestingli
furin
inhibitor
also
therapeut
interest
role
cancer
exampl
furin
inhibitor
hiv
envelop
process
includ
peptid
contain
hiv
cleavag
sequenc
amino
acid
sequenc
rekr
exampl
protein
inhibitor
furin
includ
macroglobulin
engin
contain
furin
cleavag
site
bait
potent
inhibitor
serin
proteas
notabl
advantag
furin
inhibitor
could
also
effect
numer
envelop
virus
includ
ebola
viru
influenza
viru
sar
coronaviru
recent
small
druglik
molecul
suggest
disrupt
process
bind
directli
envelop
consist
studi
show
envelop
process
sensit
mutat
proxim
distant
residu
respect
cleavag
site
final
altern
strategi
target
format
free
state
envelop
would
enhanc
prematur
dissoci
shed
associ
rel
weak
base
presenc
solubl
supernat
cell
express
envelop
sensit
associ
mutat
howev
design
strategi
imped
absenc
structur
detail
interact
figur
thu
knowledg
agent
design
disrupt
associ
exploit
date
attract
strategi
entri
inhibit
target
step
entri
process
figur
bind
therapeut
molecul
cr
bind
site
altern
bind
site
cr
note
cr
site
present
engag
thu
transient
natur
consequ
site
antagonist
target
free
conform
site
antagonist
would
target
receptorbound
conform
figur
numer
exampl
therapeut
target
receptor
bind
site
exampl
small
molecul
thought
bind
site
therebi
inhibit
hiv
entri
howev
mechan
action
current
debat
similar
effort
led
discoveri
small
molecul
broad
efficaci
exampl
monoclon
antibodi
bind
site
therebi
inhibit
entri
lectin
carbohydr
bind
protein
inhibit
receptor
interact
bind
mannos
sugar
rel
nonspecif
manner
nonetheless
high
efficaci
eg
lectin
cyanoviron
exhibit
ec
nm
strain
hiv
similar
manner
silver
nanoparticl
recent
shown
bind
inhibit
bind
presum
rel
nonspecif
manner
note
nonspecif
bind
molecul
lectin
silver
nanoparticl
might
advantag
case
hiv
present
possibl
target
multipl
hiv
strain
perhap
multipl
envelop
virus
betulin
acid
deriv
exampl
small
molecul
target
loop
ie
cr
bind
site
interestingli
peptid
deriv
bind
exampl
alloster
inhibitor
simultan
disrupt
bind
cr
final
sever
exampl
entri
inhibitor
target
bind
site
cellular
target
cr
exampl
drug
maraviroc
brandnam
selzentri
celestri
us
fda
approv
therapi
treatment
hiv
infect
target
moreov
monoclon
antibodi
ibalizumab
target
respect
current
clinic
trial
summari
numer
strategi
target
receptor
bind
step
hiv
entri
exhibit
promis
date
surpris
success
target
tether
conform
transient
natur
half
life
estim
minut
rational
behind
therapi
block
format
thermodynamicallyfavor
fusion
state
figur
note
peptid
correspond
part
term
fuzeon
enfuvirtid
us
fda
approv
therapi
human
success
enfuvirtid
import
two
aspect
first
effici
therapi
resist
observ
rel
rare
second
enfuvirtid
provid
proof
principl
transient
metast
target
envelop
feasibl
hiv
recent
strategi
exploit
peptid
compos
unnatur
amino
acid
increas
resist
proteolysi
efficaci
multipl
hiv
strain
base
entri
model
present
figur
interest
altern
strategi
employ
use
three
five
helix
bundl
version
envelop
fusion
state
miss
three
one
respect
provid
bind
site
virion
bound
tether
state
exampl
small
molecul
design
inhibit
hiv
entri
bind
expos
hydrophob
pocket
therebi
disrupt
format
fusion
state
howev
mechan
action
could
significantli
complex
final
rational
target
tether
state
support
neutral
abil
antibodi
bind
mper
epitop
also
transient
expos
late
stage
entri
mechan
importantli
base
similar
entri
mechan
hiv
envelop
virus
transient
metast
state
presum
viabl
target
gener
review
consid
challeng
opportun
develop
entri
inhibitor
target
hiv
envelop
envelopemedi
hiv
entri
well
orchestr
event
consist
multipl
conform
metast
structur
biolog
mutagenesi
studi
given
import
insight
envelop
function
howev
mani
detail
would
critic
structurebas
therapeut
miss
mutagenesi
studi
suggest
envelop
target
rich
environ
numer
potenti
site
therapeut
intervent
given
exampl
small
molecul
peptid
protein
antibodi
hiv
entri
inhibitor
importantli
us
fda
approv
therapi
target
viral
cellular
target
well
numer
therapi
clinic
trial
earli
stage
develop
consequ
anticip
arriv
multipl
new
entri
inhibitor
hiv
particular
well
envelop
virus
ebola
viru
influenza
viru
sar
coronaviru
near
futur
box
envelop
protein
virus
possess
outer
lipid
membran
deriv
host
term
envelop
virus
virus
possess
protein
coat
term
nonenvelop
envelop
virus
includ
hiv
siv
contain
protein
mediat
entri
surfac
unit
su
bind
receptor
transmembran
unit
tm
enabl
membran
fusion
hiv
siv
su
tm
protein
respect
ebola
viru
influenza
viru
paramyxoviru
sar
coronaviru
su
protein
term
respect
tm
protein
respect
importantli
high
resolut
structur
inform
avail
domain
protein
box
discoveri
entri
inhibitor
entri
inhibitor
discov
number
differ
strategi
monoclon
antibodi
ii
phage
display
iii
small
molecul
screen
iv
structurebas
drug
design
monoclon
antibodi
bind
specif
hiv
envelop
block
entri
found
patient
expos
hiv
phage
display
perform
expos
librari
phage
express
short
peptid
region
similar
techniqu
employ
bacteria
yeast
librari
hiv
envelop
cr
small
molecul
screen
perform
use
vitro
bind
cell
base
assay
final
ration
drug
design
employ
target
envelop
case
highresolut
structur
known
use
silico
method
note
interest
aspect
discoveri
techniqu
potenti
direct
target
transient
conform
envelop
shown
figur
number
correspond
strain
put
glycosyl
site
denot
asterisk
domain
abbrevi
sp
signal
peptid
conserv
domain
variabl
domain
fp
fusion
peptid
heptad
repeat
sometim
refer
nhelix
dl
disulfid
loop
heptad
repeat
sometim
refer
chelix
mper
membran
proxim
ectodomain
region
tm
transmembran
domain
cd
cytoplasm
domain
high
resolut
structur
inform
avail
domain
color
figur
ribbon
diagram
hiv
core
clariti
antibodi
domain
bound
core
shown
b
ribbon
diagram
siv
ectodomain
structur
disulfid
loop
domain
color
cyan
yellow
red
respect
space
fill
represent
core
residu
form
interact
residu
strain
number
cr
residu
strain
number
color
purpl
pink
respect
base
xray
structur
core
complex
domain
antibodi
bound
cr
bind
site
residu
form
put
interact
disulfid
loop
residu
strain
number
color
yellow
base
mutagenesi
studi
b
space
fill
represent
ectodomain
residu
form
put
interact
residu
strain
number
color
green
base
mutagenesi
studi
orient
ident
shown
figur
cr
target
cell
color
purpl
pink
respect
color
green
loop
color
light
green
domain
shown
fusion
peptid
light
purpl
cyan
disulfid
loop
yellow
red
mper
orang
first
step
free
state
bind
receptor
subsequ
loop
engag
cr
form
receptorbound
state
ii
next
step
dissoci
undergo
larg
conform
chang
newli
expos
fusion
peptid
insert
target
cell
membran
form
tether
state
iii
final
step
interact
therebi
bring
target
viru
membran
close
proxim
allow
membran
fusion
viru
entri
